IGXT (Mkap $34 M) 2 US-Zulassungsanträge im 4Q + weiteres Produkt wartet auf FDA Zulassung (Seite 66)
eröffnet am 27.07.16 17:27:05 von
neuester Beitrag 21.03.24 14:04:18 von
neuester Beitrag 21.03.24 14:04:18 von
Beiträge: 1.197
ID: 1.235.830
ID: 1.235.830
Aufrufe heute: 0
Gesamt: 195.666
Gesamt: 195.666
Aktive User: 0
ISIN: US45822R1014 · WKN: A0RP0X · Symbol: 0IL
0,1340
EUR
-8,84 %
-0,0130 EUR
Letzter Kurs 13.05.24 Gettex
Neuigkeiten
08.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
21.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9998 | +169,42 | |
| 1,0000 | +33,33 | |
| 0,5500 | +22,22 | |
| 15,348 | +19,53 | |
| 1,6500 | +17,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,5001 | -17,43 | |
| 5,2500 | -19,23 | |
| 5,2300 | -20,64 | |
| 0,7800 | -29,73 | |
| 2.849,50 | -83,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 54.733.062 von Popeye82 am 13.04.17 14:22:14
neee bin ich ganz bestimmt nicht !
Der Name stammt von einer Platte zu der wir früher gefeiert haben
https://m.youtube.com/watch?v=GJFLYEIZUWI
Greetz
neee bin ich ganz bestimmt nicht !Der Name stammt von einer Platte zu der wir früher gefeiert haben
https://m.youtube.com/watch?v=GJFLYEIZUWI
Greetz
Antwort auf Beitrag Nr.: 54.732.804 von backonplastic am 13.04.17 13:44:41
backonplastic
________
Was bedeutet der Name?
Sind Sie ein ANTIgreenrevoluzzer???
backonplastic
________
Was bedeutet der Name?
Sind Sie ein ANTIgreenrevoluzzer???
Antwort auf Beitrag Nr.: 54.732.741 von illmatix am 13.04.17 13:37:37aber GUTE !!!
Jetzt dürften wir aber mal gegen Norden hüpfen.
Die Zulassung dürfte nun EU weit gelten oder ?!?!
Jetzt dürften wir aber mal gegen Norden hüpfen.
Die Zulassung dürfte nun EU weit gelten oder ?!?!
RIZAPORT(R)Marketing Approval in Luxembourg
www.intelgenx.com/investors/press-releases/press-release-det…
www.intelgenx.com/investors/press-releases/press-release-det…
Antwort auf Beitrag Nr.: 54.703.316 von Biohero am 08.04.17 18:15:32http://www.military-technologies.net/2017/04/13/intelgenx-te…
NEWS
"Posted on 13 April 2017 by Military News
IntelGenx Technologies Corp. (IGXT: OTCQX U.S.) | IntelGenx and RedHill Biopharma Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg"
NEWS
"Posted on 13 April 2017 by Military News
IntelGenx Technologies Corp. (IGXT: OTCQX U.S.) | IntelGenx and RedHill Biopharma Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg"
Trading Spotlight
Mit dem aktuellen Darlehen und Cash das sie haben reicht es locker bis mindestens 2020 auszukommen .Ab Mai dürfte es hier wieder sehr interessant werden ich warte noch ein paar tage ab um zu sehen was da in Syrien passiert wenn da nichts eskaliert werde ich hier aufjedenfall zukaufen .
kleines Update :
Tadalafil: In Mai gibts daten von einer kleinen Studie die gerade läuft danach wird man die Zulassung beantragen in Juni oder Juli . Wie zu erwarten war ist das interesse an Tadalafil enorm gestiegen nach dem Patent-Deal mit Lilly laut angaben vom ceo sind selbst Big Pharma an dem Produkt interessiert .
Rizaport: US-Zulassungsantrag soll in Juli oder August eingereicht werden
Montelukast : Phase 2a Studie soll in diesem oder nächsten Monat starten
Opioid Dependence (Par Pharma) : Update bzgl Patentstreitigkeit in Juni erwartet
Transkript / Konferenz Jahresergebniss
http://s2.q4cdn.com/790425727/files/doc_financials/2016/fina…
Tadalafil :
Over the course of last year, we completed the manufacturing of the submission batches and stability studies are ongoing. Also ongoing is the pivotal bio study that is required for inclusion in the submission trial. The result of that study is expected to be available in May, and provided a positive outcome of this study, we planned to file the 505 (b)(2) NDA in the June, July timeframe .
I cannot be specific but what I can tell you is that since we announced that we are in settlement negotiations with Lilly and–initially achieved based on exclusive license.
The interest in partnering with us has risen pretty dramatically and even more so and now that we received an exclusive license. I cannot be specific obviously, I cannot disclose
any names, what I can say qualitatively is that we are discussing the opportunity with several potential partners from very large to mid-size and small and the entire range and I think I need to leave it at that.
Opioid Dependence (Par Pharma):
The judge is currently considering our motion
to reopen and while we expect to obtain the same ruling as
ever received it in case that might not be the case we are prepared to appeal the ruling
.
In addition to that litigation Mylan has also filed an IPR against this very same 514 patent that IPR is based on new evidence and there is some indication that–Mylan might be successful with that IPR which again means for IntelGenx and Par that the patent will disappear and we will then most likely be free and clear. We expect a ruling for the fourth trial on the process patent that was held in November to be issued in June of this year.
kleines Update :
Tadalafil: In Mai gibts daten von einer kleinen Studie die gerade läuft danach wird man die Zulassung beantragen in Juni oder Juli . Wie zu erwarten war ist das interesse an Tadalafil enorm gestiegen nach dem Patent-Deal mit Lilly laut angaben vom ceo sind selbst Big Pharma an dem Produkt interessiert .
Rizaport: US-Zulassungsantrag soll in Juli oder August eingereicht werden
Montelukast : Phase 2a Studie soll in diesem oder nächsten Monat starten
Opioid Dependence (Par Pharma) : Update bzgl Patentstreitigkeit in Juni erwartet
Transkript / Konferenz Jahresergebniss
http://s2.q4cdn.com/790425727/files/doc_financials/2016/fina…
Tadalafil :
Over the course of last year, we completed the manufacturing of the submission batches and stability studies are ongoing. Also ongoing is the pivotal bio study that is required for inclusion in the submission trial. The result of that study is expected to be available in May, and provided a positive outcome of this study, we planned to file the 505 (b)(2) NDA in the June, July timeframe .
I cannot be specific but what I can tell you is that since we announced that we are in settlement negotiations with Lilly and–initially achieved based on exclusive license.
The interest in partnering with us has risen pretty dramatically and even more so and now that we received an exclusive license. I cannot be specific obviously, I cannot disclose
any names, what I can say qualitatively is that we are discussing the opportunity with several potential partners from very large to mid-size and small and the entire range and I think I need to leave it at that.
Opioid Dependence (Par Pharma):
The judge is currently considering our motion
to reopen and while we expect to obtain the same ruling as
ever received it in case that might not be the case we are prepared to appeal the ruling
.
In addition to that litigation Mylan has also filed an IPR against this very same 514 patent that IPR is based on new evidence and there is some indication that–Mylan might be successful with that IPR which again means for IntelGenx and Par that the patent will disappear and we will then most likely be free and clear. We expect a ruling for the fourth trial on the process patent that was held in November to be issued in June of this year.
Tja, die Intelgenx, die gehört auch den Aktien, die ich nie anpacken will, um sie dann zu kaufen (das passierte dann mehrmals). Derzeit bin ich raus.
Was mich irritiert, ist, dass hier so ein Alleinstellungsmerkmal glaubhaft gemacht wird (oder nur von mir fälschlicherweise so gedeutet wurde), dabei gibt es ja auch ein deutsches Unternehmen (www.ltslohmann.de).
Kann jemand Hilfestellung geben?
Was mich irritiert, ist, dass hier so ein Alleinstellungsmerkmal glaubhaft gemacht wird (oder nur von mir fälschlicherweise so gedeutet wurde), dabei gibt es ja auch ein deutsches Unternehmen (www.ltslohmann.de).
Kann jemand Hilfestellung geben?
IntelGenx Presents at the 13th International Conference on Alzheimer's and Parkinson's Diseases
SAINT LAURENT, QUEBEC -- (Marketwired) -- 04/04/17 -- IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCQX: IGXT)(the "Company" or "IntelGenx") announced today that Dr. Horst Zerbe, its President and Chief Executive Officer, and Prof. Ludwig Aigner, Paracelsus University Salzburg, Austria, discussed the Company's Montelukast VersaFilm™ project during a poster presentation at the 13th International Conference on Alzheimer's & Parkinson's Diseases held on March 29 - April 2, 2017 in Vienna, Austria.
Entitled "Repurposing Of The Anti-asthmatic Drug Montelukast For The Treatment Of Alzheimer's Disease," the poster presentation reviewed the Company's research on Montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain. IntelGenx is working to develop a Montelukast oral film product based on its VersaFilm™ proprietary thin film technology by using the drug Montelukast, which is currently approved by the U.S. Food and Drug Administration for the treatment of asthma and has also demonstrated potential for the treatment of degenerative diseases of the brain.
"We were very excited to have the opportunity to present at such a renowned and important conference, in front of leading medical and scientific professionals from around the word," said Dr. Zerbe. "IntelGenx' recent research demonstrates the strong potential of our Montelukast VersaFilm™ as a more effective delivery system for CNS applications, especially degenerative brain diseases, and we believe these compelling results were well-received by conference participants."
As the brain ages, it loses its ability to generate new cells, while existing cells lose functionality and the ability to prevent neuroinflammation. Furthermore, the aged brain tends to produce higher levels of inflammatory agents such as leukotrienes, resulting in neuroinflammation and cognitive impairment. There is evidence that leukotriene receptor antagonists, such as Montelukast sodium, have the potential to reduce neuroinflammation and restore brain cell function. Such treatments can be effective for treating various neurodegenerative diseases and conditions, including Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Huntington's Disease, spinal cord and brain injuries, and stroke.
IntelGenx is working to repurpose Montelukast as a therapeutic to treat these neurodegenerative diseases by re-formulating Montelukast into an oral film-based platform with improved bioavailability. Presently, Montelukast is marketed as Singulair, a once daily tablet for the chronic treatment of asthma and seasonal allergic rhinitis, which suffers from poor and inconsistent bioavailability. IntelGenx' proprietary VersaFilm technology offers several advantages over tablets, including the avoidance and minimization of first-pass-effects, improved API bioavailability, lower dosing and toxicity, easier swallowing and better patience compliance.
In a recent Phase I study, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. Of importance for any central nervous system ("CNS") active drugs, IntelGenx detected Montelukast in the cerebrospinal fluid of healthy volunteers who were treated with Montelukast VersaFilm™, clearly indicating blood brain barrier penetrance. Also, in contrast to many other CNS-penetrating drugs, Montelukast had an excellent safety and tolerability profile. IntelGenx is preparing a Phase II trial to demonstrate efficacy of the Montelukast VersaFilm™ to improve cognitive function in Alzheimer's Disease.
SAINT LAURENT, QUEBEC -- (Marketwired) -- 04/04/17 -- IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCQX: IGXT)(the "Company" or "IntelGenx") announced today that Dr. Horst Zerbe, its President and Chief Executive Officer, and Prof. Ludwig Aigner, Paracelsus University Salzburg, Austria, discussed the Company's Montelukast VersaFilm™ project during a poster presentation at the 13th International Conference on Alzheimer's & Parkinson's Diseases held on March 29 - April 2, 2017 in Vienna, Austria.
Entitled "Repurposing Of The Anti-asthmatic Drug Montelukast For The Treatment Of Alzheimer's Disease," the poster presentation reviewed the Company's research on Montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain. IntelGenx is working to develop a Montelukast oral film product based on its VersaFilm™ proprietary thin film technology by using the drug Montelukast, which is currently approved by the U.S. Food and Drug Administration for the treatment of asthma and has also demonstrated potential for the treatment of degenerative diseases of the brain.
"We were very excited to have the opportunity to present at such a renowned and important conference, in front of leading medical and scientific professionals from around the word," said Dr. Zerbe. "IntelGenx' recent research demonstrates the strong potential of our Montelukast VersaFilm™ as a more effective delivery system for CNS applications, especially degenerative brain diseases, and we believe these compelling results were well-received by conference participants."
As the brain ages, it loses its ability to generate new cells, while existing cells lose functionality and the ability to prevent neuroinflammation. Furthermore, the aged brain tends to produce higher levels of inflammatory agents such as leukotrienes, resulting in neuroinflammation and cognitive impairment. There is evidence that leukotriene receptor antagonists, such as Montelukast sodium, have the potential to reduce neuroinflammation and restore brain cell function. Such treatments can be effective for treating various neurodegenerative diseases and conditions, including Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Huntington's Disease, spinal cord and brain injuries, and stroke.
IntelGenx is working to repurpose Montelukast as a therapeutic to treat these neurodegenerative diseases by re-formulating Montelukast into an oral film-based platform with improved bioavailability. Presently, Montelukast is marketed as Singulair, a once daily tablet for the chronic treatment of asthma and seasonal allergic rhinitis, which suffers from poor and inconsistent bioavailability. IntelGenx' proprietary VersaFilm technology offers several advantages over tablets, including the avoidance and minimization of first-pass-effects, improved API bioavailability, lower dosing and toxicity, easier swallowing and better patience compliance.
In a recent Phase I study, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. Of importance for any central nervous system ("CNS") active drugs, IntelGenx detected Montelukast in the cerebrospinal fluid of healthy volunteers who were treated with Montelukast VersaFilm™, clearly indicating blood brain barrier penetrance. Also, in contrast to many other CNS-penetrating drugs, Montelukast had an excellent safety and tolerability profile. IntelGenx is preparing a Phase II trial to demonstrate efficacy of the Montelukast VersaFilm™ to improve cognitive function in Alzheimer's Disease.
Durchsuchen
